Department of Rheumatology, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary.
Eur Arch Otorhinolaryngol. 2014 May;271(5):1057-65. doi: 10.1007/s00405-013-2666-y. Epub 2013 Aug 25.
Microbial biofilms have been implicated in the pathogenesis of chronic rhinosinusitis with nasal polyposis (CRSwNP). Intranasal application of corticosteroids (INCS) is a reliable option in the management of CRSwNP. INCS medication has been suspected to influence the presence and thickness of microbial biofilms and inflammatory cell patterns in CRSwNP. Two series of identical nasal polyps obtained from non-allergic patients with CRSwNP (n = 56), who underwent endoscopic sinus surgery (ESS), were processed to hematoxylin-eosin (H.E.) and Gram staining, respectively. Patients were recruited into three groups. Group A (n = 21) consisted of patients with continuous preoperative INCS treatment. In group B (n = 17), patients were never treated by INCS, while in group C (n = 18) INCS medication was stopped at least 6 months before ESS. Biofilm positivity varied from 76.4 to 88.8% in different subject groups. These values and average thickness of biofilms did not reach statistically significant levels (Mann-Whitney's U probe, p > 0.05) in different patient groups. In contrast, microscopic pattern and numbers of predominant inflammatory cell populations displayed obvious differences according to INCS treatment (Mann-Whitney's U probe, p < 0.001). According to these observations, INCS treatment does not affect the presence and thickness of microbial biofilms in CRSwNP. In contrast, it has significant effects on the pattern of inflammatory cells infiltrating the subepithelial layer, which might result in beneficially altered extracellular matrix production and cytokine release.
微生物生物膜与慢性鼻-鼻窦炎伴鼻息肉(CRSwNP)的发病机制有关。鼻内应用皮质类固醇(INCS)是治疗 CRSwNP 的可靠选择。INCS 药物被怀疑会影响 CRSwNP 中微生物生物膜的存在和厚度以及炎症细胞模式。从接受内镜鼻窦手术(ESS)的非变应性 CRSwNP 患者(n=56)中获得了两系列相同的鼻息肉,分别进行了苏木精-伊红(H.E.)和革兰氏染色处理。患者被分为三组。A 组(n=21)由持续术前 INCS 治疗的患者组成。B 组(n=17)的患者从未接受过 INCS 治疗,而 C 组(n=18)的患者在 ESS 前至少 6 个月停止了 INCS 治疗。生物膜阳性率在不同的亚组中从 76.4%到 88.8%不等。这些值和生物膜的平均厚度在不同的患者组中未达到统计学显著水平(Mann-Whitney U 检验,p>0.05)。相比之下,根据 INCS 治疗,炎症细胞主要群体的微观模式和数量显示出明显的差异(Mann-Whitney U 检验,p<0.001)。根据这些观察结果,INCS 治疗不会影响 CRSwNP 中微生物生物膜的存在和厚度。相反,它对浸润上皮下层的炎症细胞模式有显著影响,这可能导致细胞外基质产生和细胞因子释放发生有益改变。